Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial

被引：0
|
作者：
Pressiani, T. [1 ]
Balsano, R. [2 ]
Giordano, L. [3 ]
Milella, M. [4 ,5 ]
Bergamo, F. [6 ]
Bozzarelli, S. [7 ]
Noventa, S. [8 ]
Ferrari, D. [9 ]
Scartozzi, M. [10 ,11 ]
Parra, H. J. Soto [12 ]
Auriemma, A. [4 ,5 ]
Solda, C. [13 ]
Zaniboni, A. [8 ]
Zecchetto, C. [4 ,5 ]
Rizzato, M. D. [6 ]
Rimassa, L. [14 ]
Santoro, A. [15 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Rozzano, Italy
[2] Humanitas Univ, IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Dept Biomed Sci,Humanitas Canc Ctr, Rozzano, Italy
[3] IRCSS Humanitas Res Hosp, Biostat Unit, Humanitas Canc Ctr, Rozzano, Italy
[4] Univ Verona, Sect Innovat Biomed, Dept Engn Innovat Med DIMI, Oncol Area, Verona, Italy
[5] Verona Univ & Hosp Trust, Verona, Italy
[6] IRCCS, Veneto Inst Oncol IOV, Dept Oncol, Oncol 1, Padua, Italy
[7] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Rozzano, Italy
[8] Fdn Poliambulanza Ist Osped, Med Oncol Unit, Brescia, Italy
[9] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Med Oncol Dept, Med Oncol & Hematol Unit,AO S Paolo, Milan, Italy
[10] Univ Monserrato, Med Oncol, Monserrato, Italy
[11] Univ Hosp, Monserrato, Italy
[12] Azienda Osped Univ Policlin San Marco, Oncol Med, Catania, Italy
[13] IRCCS, Veneto Inst Oncol IOV, Oncol 1, Dept Oncol, Padua, Italy
[14] Humanitas Univ, Med Oncol & Hematol Unit, Dept Biomed Sci, Humanitas Canc Ctr,IRCCS Humanitas Res Hosp, Rozzano, Italy
[15] Humanitas Univ, Med Oncol & Hematol Unit, Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Rozzano, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.291
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285P
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [31] A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract
    Karachaliou, Niki
    Polyzos, Aris
    Kentepozidis, Nikolaos
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vardakis, Nikolaos
    Kalykaki, Antonia
    Milaki, Georgia
    Georgoulias, Vassilis
    Androulakis, Nikolaos
    ONCOLOGY, 2010, 78 (5-6) : 356 - 360
  • [32] A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
    Chiang, N-J.
    Bai, L-Y.
    Huang, C-J.
    Chen, S-C.
    Hsiao, C-F.
    Shan, Y-S.
    Su, Y-Y.
    Chen, L.
    Chen, M-H.
    ANNALS OF ONCOLOGY, 2021, 32 : S377 - S377
  • [33] Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
    Kyung Hee Lee
    Min Kyoung Kim
    Yeol Hong Kim
    Baek Yeol Ryoo
    Ho Yeong Lim
    Hong Suk Song
    Hoon Kyo Kim
    Myung Ah Lee
    Seock Ah Im
    Heung Moon Chang
    Jae Yong Cho
    Dae Young Zang
    Bong Seog Kim
    Jun Suk Kim
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 317 - 325
  • [34] Gemcitabine and oxaliplatin combination as the first-line treatment in advanced pancreatic cancer: A multicenter phase II study
    Lee, K.
    Kim, M.
    Kim, Y.
    Ryoo, B.
    Lim, H.
    Song, H.
    Kim, H.
    Lee, M.
    Im, S.
    Chang, H.
    Cho, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
    Lee, Kyung Hee
    Kim, Min Kyoung
    Kim, Yeol Hong
    Ryoo, Baek Yeol
    Lim, Ho Yeong
    Song, Hong Suk
    Kim, Hoon Kyo
    Lee, Myung Ah
    Im, Seock Ah
    Chang, Heung Moon
    Cho, Jae Yong
    Zang, Dae Young
    Kim, Bong Seog
    Kim, Jun Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 317 - 325
  • [36] A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs).
    Shroff, Rachna T.
    Borad, Mitesh J.
    Xiao, Lianchun
    Kaseb, Ahmed Omar
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Raghav, Kanwal Pratap Singh
    Iwasaki, Michiko
    Masci, Peter
    Ramanathan, Ramesh K.
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
    Wen Zhang
    Chunxia Du
    Yongkun Sun
    Lin Yang
    Chengxu Cui
    Zhichao Jiang
    Chengfeng Wang
    Jinwang Wang
    Aiping Zhou
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 655 - 660
  • [38] Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
    Zhang, Wen
    Du, Chunxia
    Sun, Yongkun
    Yang, Lin
    Cui, Chengxu
    Jiang, Zhichao
    Wang, Chengfeng
    Wang, Jinwang
    Zhou, Aiping
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 655 - 660
  • [39] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Qin, Yan-ru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 340 - 340
  • [40] Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO)
    Chen, Inna Markovna
    Johansen, Julia S.
    Theile, Susann
    Madsen, Kasper
    Dajani, Olav
    Lorentzen, Torben
    Zimmers, Teresa
    Nielsen, Dorte
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345